Table 4.
Prevalence of hepatitis E IgG antibody (anti-HEV IgG) among pre-travel participants who were born in, lived in, or traveled to individual highly endemic countries*
| Country | Total | No. of anti-HEV IgG (+) | % Anti-HEV IgG (+) |
|---|---|---|---|
| Ethiopia | 28 | 8 | 29 |
| Namibia | 24 | 4 | 17 |
| Turkey | 63 | 10 | 16 |
| Cuba | 21 | 3 | 14 |
| Egypt | 84 | 11 | 13 |
| Burma | 25 | 3 | 12 |
| Uganda | 26 | 3 | 12 |
| Botswana | 35 | 4 | 11 |
| Morocco | 54 | 6 | 11 |
| Ghana | 51 | 5 | 10 |
| Nigeria | 31 | 3 | 10 |
| India | 223 | 19 | 9 |
| China | 208 | 14 | 7 |
| Kenya | 104 | 7 | 7 |
| Vietnam | 100 | 6 | 6 |
| Mexico | 370 | 21 | 6 |
| Nepal | 37 | 2 | 5 |
| Indonesia | 50 | 2 | 4 |
*
Results limited to countries to which ≥ 20 participants reported history of travel. Participants were evaluated by the Boston Area Travel Medicine Network from January 2009 to September 2010.